Syros Pharmaceuticals

153 articles about Syros Pharmaceuticals

• Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

  3/15/2022

  Syros Pharmaceuticals today reported financial results for the quarter and full-year ended December 31, 2021, and provided an update on recent accomplishments and upcoming events.

• Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022

  3/9/2022

  Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

• Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022

  3/8/2022

  Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) Annual Meeting 2022.

• Syros to Participate in Upcoming Virtual Investor Conferences in March 2022

  2/28/2022

  Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March.

• Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS

  2/2/2022

  Syros Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS).

• Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company

  1/10/2022

  Syros Pharmaceuticals (

• Syros to Participate in Upcoming Investor Conferences

  11/16/2021

  Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.

• Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

  11/5/2021

  Syros Pharmaceuticals today reported financial results for the quarter ended September 30, 2021, and provided an update on recent accomplishments and upcoming events.

• Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021

  10/29/2021

  Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, November 5, 2021 to report its third quarter 2021 financial results and provide a corporate update.

• Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4) - Oct 13, 2021

  10/13/2021

  Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of an inducement stock option award to Jason Haas, the Company’s recently hired Chief Financial Officer, in accordance with Mr. Haas’s employment offer letter.

• Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

  10/12/2021

  Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer.

• Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia

  9/29/2021

  Syros Pharmaceuticals today announced that the first patient has been dosed in the dose confirmation study of SY-2101, a novel oral form of arsenic trioxide (ATO).

• Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4) - Sep 28, 2021

  9/28/2021

  Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of an inducement stock option award to Conley Chee, the Company’s recently hired Chief Commercial Officer, in accordance with Mr. Chee’s employment offer letter.

• Syros Announces Appointment of Conley Chee as Chief Commercial Officer

  9/27/2021

  Syros Pharmaceuticals today announced the appointment of Conley Chee as the company’s first Chief Commercial Officer.

• Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer

  9/20/2021

  Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new data from the dose-escalation portion of the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrating clinical activity at tolerable doses as a single agent across multiple tumor types.

• Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021

  9/13/2021

  Management to Host Conference Call on Monday, September 20, 2021 at 4:00 p.m. ET

• Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors

  9/10/2021

  Syros Pharmaceuticals today announced the appointment of Deborah Dunsire, M.D., to the Company’s Board of Directors.

• Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

  9/9/2021

  Syros Pharmaceuticals today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine.

• Syros to Present at Upcoming Investor Conferences in September 2021

  9/7/2021

  Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at two upcoming investor conferences in September.

• Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

  8/5/2021

  Syros Pharmaceuticals today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events.